Prevalence of HER3 Expression in Pancreatic Cancer Patients Treated With Systemic Chemotherapy.

ABSTRACT:

Background

Although activation of human epidermal growth factor receptor 3 (HER3) is linked to resistance to targeted therapies in several cancer types, the HER3 expression profile during pancreatic cancer treatment remains unknown.

Aims

We evaluated the HER3 expression status after chemotherapy for pancreatic cancer and its association with clinicopathological features and clinical outcomes.

Materials & methods

We included patients with pancreatic cancer who underwent chemotherapy and whose post-treatment archival tissue specimens were collected. HER3 expression was retrospectively assessed by immunohistochemistry scoring (0, 1+, 2+, and 3+) of the membranous staining intensity.

Results

HER3 expression after chemotherapy was evaluated in 41 patients, with matc

SUBMITTER: Satake T 

PROVIDER: S-EPMC11626478 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature